• Academy, Ophthalmic Community Challenge FDA Plan, Ensure Access to Compounded Moxifloxacin


    The Academy recommends that the U.S. Food and Drug Administration retain moxifloxacin on the bulk substance list, ensuring continued access to compounded moxifloxacin for our patients.